CAR-T cell therapy: Where are we now, and where are we heading?

Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. Furthermore, CAR-T cells have shown promising potential for expanding their therapeutic applications to diverse areas, inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jia-Yi, Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629745/
https://www.ncbi.nlm.nih.gov/pubmed/37941917
http://dx.doi.org/10.1097/BS9.0000000000000173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629745/
https://www.ncbi.nlm.nih.gov/pubmed/37941917
http://dx.doi.org/10.1097/BS9.0000000000000173

Ejemplares similares